Femasys shares are trading higher after the company announced FDA clearance to continue enrollment in the final phase of its FINALE trial for FemBloc and entered agreements to issue $12M in notes and warrants, potentially raising up to $58M.

2025-11-03 21:35

Femasys宣布FDA批准继续参加FemBloc FINALEE试验的最后阶段，并达成发行1200万美元票据和期权的协议，可能筹集高达5800万美元的资金后，Femasys股价走高。